Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia, Myeloid, Chronic-Phase 6Leukemia 4Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 21fludarabine 20fludarabine phosphate 17Tacrolimus 12thymoglobulin 11Whole-Body Irradiation 11Busulfan 10Azacitidine 10Mycophenolic Acid 9Methotrexate 9Thiotepa 8Melphalan 8Antilymphocyte Serum 8venetoclax 7AP 1903 reagent 7Rituximab 6Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5merphos 4aldesleukin 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Interleukin-2 4Dexamethasone 4enasidenib 3Tretinoin 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Homoharringtonine × Myeloid × Clear all
NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

M.D. Anderson Cancer Center

Phase 1/2 Terminated
24 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡